<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02608515</url>
  </required_header>
  <id_info>
    <org_study_id>NIPMS-GENESIS-MM-GRC-002</org_study_id>
    <nct_id>NCT02608515</nct_id>
  </id_info>
  <brief_title>A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease</brief_title>
  <acronym>LEGEND</acronym>
  <official_title>A Retrospective Chart Review Study of the Outcomes of Second Line Therapy With LEnalidomide/Dexamethasone in Greek Patients With Relapsed/Refractory Multiple MyEloma and the Treatment PatterNs Following Progressive Disease, &quot;The LEGEND Study&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genesis Pharma S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genesis Pharma S.A.</source>
  <brief_summary>
    <textblock>
      This non-interventional retrospective chart review study aims to evaluate the clinical
      outcomes of patients with RRMM receiving lenalidomide/dexamethasone (Len/Dex) treatment at
      1st relapse and the treatment patterns following progressive disease as part of the routine
      clinical practice in Greece.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the 12-month PFS rate in patients treated with Len/Dex at 1st relapse</measure>
    <time_frame>12 months</time_frame>
    <description>PFS rate</description>
  </primary_outcome>
  <enrollment type="Actual">207</enrollment>
  <condition>Relapsed/Refractory Multiple Myeloma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        A total of approximately 220 patients with RRMM that started second-line treatment with
        lenalidomide/dexamethasone between 01 January 2009 to 01 March 2014 and who fulfill all
        study-specific eligibility criteria at the investigators' discretion will be included in
        this study
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must fulfill ALL of the following criteria:

          -  Subjects of both genders, aged 18 years or older

          -  Subjects must have a relapsed or refractory MM diagnosis according to IMWG or EBMT
             criteria

          -  Subjects must have initiated second-line therapy with lenalidomide/dexamethasone
             according to the approved products' Summary of Product Characteristics (SmPC) between
             01 January 2009 and 01 March 2014

          -  Subjects must have available medical files/records and detailed historical data on
             their disease course and clinical management

          -  Provision of signed ICF for collecting and analyzing medical data pertinent to the
             objectives of this study

        Exclusion Criteria:

        For the candidate subjects NONE of the following criteria should apply:

          -  Prior malignancy (within the 3 years preceding initial diagnosis of MM)

          -  Concurrent administration of anti-cancer regimens for malignancies other than MM
             between the time of initial MM diagnosis and time of second relapse

          -  Subject participation in an interventional study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiki Karvounis</last_name>
    <role>Study Director</role>
    <affiliation>Medical Department of Genesis Pharma SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Patra</name>
      <address>
        <city>Patra</city>
        <zip>26443</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>https://link.springer.com/article/10.1007/s00277-018-3361-2</url>
    <description>Published Manuscript</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

